Vitae’s Debt Financing Braves Renin Inhibitor Risk, FDA Wariness In Diabetes

Two lenders wade in despite harsh credit environment for biotechs.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet